Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FDA Panel Backs Johnson & Johnson COVID Booster Shot After At Least 2 Months: Bloomberg

10/15/2021 | 01:30pm EST


ę MT Newswires 2021
All news about JOHNSON & JOHNSON
04:28aJohnson & Johnson - Latest Phase 3 Data for First-in-Class TREMFYA Demonstrates Signifi..
AQ
04:03aJ&J Says Its 'Mix-and-Match' COVID-19 Booster With Pfizer Vaccine Shows Increase in Ant..
MT
02:06aCovid-19 Vaccination - Federal Govt Approves Booster Dose
AQ
12/05Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of B..
PR
12/04Covid-19 - Nigeria Approves Booster Doses for Enhanced Protection
AQ
12/04Federal Contractor And Subcontractor Vaccine Mandate Temporarily Enjoined In Kentucky, ..
AQ
12/03Janssen to Showcase Progress on Respiratory Syncytial Virus (RSV) Vaccine Candidate at ..
PR
12/03Johnson & Johnson's Janssen Says Phase 3b Trial of Active Psoriatic Arthritis Treatment..
MT
12/03JOHNSON & JOHNSON : Latest Phase 3 Data for First-in-Class TREMFYA« (guselkumab) Demonstra..
PU
12/03Johnson & Johnson's Janssen Says Psoriatic Arthritis Trial Meets Objective
DJ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 251 M - -
Net income 2021 22 542 M - -
Net Debt 2021 493 M - -
P/E ratio 2021 19,2x
Yield 2021 2,62%
Capitalization 420 B 420 B -
EV / Sales 2021 4,46x
EV / Sales 2022 4,15x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 159,38 $
Average target price 184,65 $
Spread / Average Target 15,9%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641
ABBVIE INC.8.18%210 113